G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
A drug that hits the exact mutation plus a drug that hits every RAS protein, so the tumour cannot escape through a wild-type RAS cousin.
ESMO GI 2026: 50% ORR and 97% DCR in second-line RAS G12D metastatic PDAC, with a manageable safety profile. Rationale is vertical suppression of adaptive RAS reactivation.
Pages like this
not linked directly; found by shared links- IdeaRAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
Shares Zoldonrasib, Daraxonrasib, KRAS, Pancreatic ductal adenocarcinoma.
- CompanyQuanta Therapeutics
Shares Daraxonrasib, RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.
- CompanyRevolution Medicines
Shares Zoldonrasib, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialRASolute 302
Shares Daraxonrasib, KRAS, Pancreatic ductal adenocarcinoma.
- ProductMRTX1133
Shares RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Daraxonrasib, KRAS, Pancreatic ductal adenocarcinoma.
- IdeaTurn a brake back on: drugs that reactivate the PP2A phosphatase
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductElironrasib
Shares RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.